Suggested remit: To appraise the clinical and cost effectiveness of tenecteplase within its marketing authorisation for thrombolytic treatment of acute ischaemic stroke.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6306

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Boehringer Ingelheim
Others Department of Health and Social Care
  NHS England
Patient carer groups Arrhythmia Alliance
  Blood Pressure UK (formerly Blood Pressure Association)
  Brain and Spinal Injury Charity (BASIC)
  Brain and Spine Foundation
  Brain Charity
  British Cardiac Patients Association
  Cardiovascular Care Partnership
  Circulation Foundation
  Different Strokes
  Neurological Alliance
  Pumping Marvellous Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Stroke Association
  Stroke Information
  Thrombosis UK
Professional groups Association of British Clinical Diabetologists
  Association of British Neurologists
  British and Irish Association of Stroke Physicians
  British and Irish Hypertension Society
  British Cardiovascular Society
  British Dietetic Association
  British Geriatrics Society
  British Heart Foundation
  British Neuropathological Society
  British Society for Haematology
  British Society for Haemostasis and Thrombosis
  British Society of Cardiovascular Imaging
  British Society of Neuroradiologists
  Clinical Leaders of Thrombosis (CLOT)
  Haemochromatosis UK
  Institute of Neurology
  National Heart and Lung Institute
  National Neurosciences Advisory Group
  Primary Care and Community Neurology Society
  Primary Care Cardiovascular Society
  Primary Care Diabetes Society
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society of British Neurological Surgeons
  Society of Vascular Nurses
  The Vascular Society of Great Britain and Ireland
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Boehringer Ingelheim (alteplase)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Government
  Welsh Government Stroke Implementation Group
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Society for Cardiovascular Research
  Cochrane Stroke Group
  Cochrane UK
  European Council for Cardiovascular Research
  Genomics England
  King’s College London Stroke Programme
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research
  The Society for Research in Rehabilitation
  Wellcome Trust


Key events during the development of the guidance:

Date Update
13 February 2024 Invitation to participate
14 September 2023 - 12 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6306
03 August 2023 In progress. DHSC referral received
07 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual